Benign prostatic disease

References

• McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978: 15(4): 340–5
   PubMedGoogle Scholar
• Kolonel LN, Hankin JH, Lee J, et al. Nutrient intakes in relation to cancer incidence in Hawaii. Br J Cancer 1981: 44(3): 332–9
   PubMed Web of Science ®Google Scholar
• Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984: 132(3): 474–9
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Campion EW, Bouchard GR, et al. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol 1985: 121(1): 78–90
   PubMed Web of Science ®Google Scholar
• Bosch RJ. Pathogenesis of benign prostatic hyperplasia. Eur Urol 1991: 20(Suppl 1): 27–30
   PubMedGoogle Scholar
• Griffiths K, Davis P, Eaton CL, et al. Endocrine factors in the initiation, diagnosis and treatment of prostatic cancer. In: Voigt KD, Knabbe C, eds. Endocrine dependent tumors. New York: Raven Press, 1991: 83–130
   Google Scholar
• Boyle P, McGinn R, Maisonneuve P, et al. Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed. Eur Urol 1991: 20(Suppl 1): 3–10
   PubMedGoogle Scholar
• McNeal JE. The prostate gland: morphology and pathobiology. Princeton, NJ: Burroughs Wellcome, 1983 (Monographs in urology, vol 4, No. 1)
   Google Scholar
• Warwick RT, Whiteside CG, Arnold EP, et al. A urodynamic view of prostatic obstruction and the results of prostatectomy. Br J Urol 1973: 45(6): 631–45
   PubMedGoogle Scholar
• Isaacs JT, Bartsch G. Benign prostatic hyperplasia: editorial overview. Curr Opin Urol 1992: 2: 1–2
   Google Scholar
• Christensen MM, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. Urol Clin North Am 1990: 17(3): 509–16
   PubMed Web of Science ®Google Scholar
• McNeal J. Pathology of benign prostatic hyperplasia: insight into etiology. Urol Clin North Am 1990: 17(3): 477–86
   PubMed Web of Science ®Google Scholar
• Shapiro E, Becich MJ, Hartanto V, et al. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992: 147(5): 1293–7
   PubMed Web of Science ®Google Scholar
• Holtgrewe HL, Mebust WK, Dowd JB, et al. Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol 1989: 141(2): 248–53
   PubMed Web of Science ®Google Scholar
• Lytton B, Emery JM, Harvard BM. The incidence of benign prostatic obstruction. J Urol 1968: 99(5): 639–45
   PubMed Web of Science ®Google Scholar
• Meyhoff HH, Nordling J. Long term results of transurethral and transvesical prostatectomy: a randomized study. Scand J Urol Nephrol 1986: 20(1): 27–33
   PubMed Web of Science ®Google Scholar
• Roos NP, Ramsey EW. A population- based study of prostatectomy: outcomes associated with differing surgical approaches. J Urol 1987: 137(6): 1184–8
   PubMed Web of Science ®Google Scholar
• Lindner A, Golomb J, Siegel Y, et al. Local hyperthermia of the prostate gland for the treatment of benign prostatic hypertrophy and urinary retention: a preliminary report. Br J Urol 1987: 60(6): 567–71
   PubMedGoogle Scholar
• Servadio C, Leib Z, Lev A. Diseases of prostate treated by local microwave hyperthermia. Urology 1987: 30(2): 97–9
   PubMed Web of Science ®Google Scholar
• McConnell JD. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990: 17(3): 661–70
   PubMed Web of Science ®Google Scholar
• Birkoff JD. Natural history of benign prostatic hypertrophy. In: Hinman F Jr, Boyarsky S, Brendler H, et al, eds. Benign prostatic hypertrophy. New York: Springer-Verlag, 1983: 5–9
   Google Scholar
• Stoner E. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol 1992: 147(5): 1298–302
   PubMed Web of Science ®Google Scholar
• Lepor H. Alpha-adrenergic blockers in the medical management of benign prostatic hyperplasia. Curr Opin Urol 1992: 2: 26–9
   Google Scholar
• Caine M. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990: 17(3): 641–9
   PubMed Web of Science ®Google Scholar
• Lipsky BA. Urinary tract infections in men: epidemiology, pathophysiology, diagnosis and treatment. Ann Intern Med 1980: 110(2): 138–50
   Google Scholar
• Drach GW, Fair WR, Meares EM, et al. Classification of benign diseases associated with prostatic pain: prostatitis or prostatodynia? (Letter) J Urol 1978: 120(2): 266
   PubMed Web of Science ®Google Scholar
• Meares EM Jr. Prostatitis. Med Clin North Am 1991: 75(2): 405–24
   PubMed Web of Science ®Google Scholar
• Loughlin KR, Whitmore WF 3d. Managing prostate disorders in middle age and beyond. Geriatrics 1987: 42(7): 45–52, 55–6
   PubMedGoogle Scholar
• Meares EM Jr. Prostatitis. Med Clin North Am 1991: 75(2): 405–24
   PubMed Web of Science ®Google Scholar
• Meares EM Jr. Prostatitis syndromes: new perspectives about old woes. J Urol 1980: 123(2): 141–7
   PubMed Web of Science ®Google Scholar
• Meares EM Jr. Prostatitis: review of pharmacokinetics and therapy. Rev Infect Dis 1982: 4(2): 475–83
   PubMedGoogle Scholar
• Peeling WB, Griffiths GJ. Imaging of the prostate by ultrasound. J Urol 1984: 132(2): 217–24
   PubMed Web of Science ®Google Scholar
• Meares EM Jr. Infection stones of prostate gland: laboratory diagnosis and clinical management. Urology 1974: 4(5): 560–6
   PubMedGoogle Scholar
• Meares EM Jr. Chronic bacterial prostatitis: role of transurethral prostatectomy (TURP) in therapy. In: Weidner W, Brunner H, Krause W, et al, eds. Therapy of prostatitis. Munich, W Zuckschwerdt, 1986: 193–7
   Google Scholar
• Granados EA, Riley G, Salvador J, et al. Prostatic abscess: diagnosis and treatment. J Urol 1992: 148(1): 80–2
   PubMed Web of Science ®Google Scholar
• Meares EM Jr, Barbalias GA. Prostatitis: bacterial, nonbacterial, and prostatodynia. Semin Urol 1983: 1 (2): 146–54
   PubMedGoogle Scholar